Fosun Pharma Licenses Cancer, Diabetes Drugs To Sellas For $4.1 Million
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Pharmaceutical's Chongqing subsidiary has signed a potential $4.1 million deal to sell the rights to compounds for a cancer and a diabetes drug to Sellas Clinicals Holding of Switzerland.